JP7664947B2 - Ｉｌ－１７の調節因子としてのイミダゾリダジン - Google Patents

Ｉｌ－１７の調節因子としてのイミダゾリダジン Download PDF

Info

Publication number
JP7664947B2
JP7664947B2 JP2022565972A JP2022565972A JP7664947B2 JP 7664947 B2 JP7664947 B2 JP 7664947B2 JP 2022565972 A JP2022565972 A JP 2022565972A JP 2022565972 A JP2022565972 A JP 2022565972A JP 7664947 B2 JP7664947 B2 JP 7664947B2
Authority
JP
Japan
Prior art keywords
alkyl
substituted
pharma
unsubstituted
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022565972A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023524018A (ja
JP2023524018A5 (https=
JPWO2021222404A5 (https=
Inventor
ベーンナ，ドグラス
デックハット，シャーロット
ロヴィラ，アレクサンダー
ゴールドベルグ，スティーブン
クンマー，ディビッド
キース，ジョン
ウッズ，クレイグ
ローラー，ティモシー
タニス，バージニア
マーティン，コーナー
メドゥナ，スティーブン
マッカーヴァー，ステファン
ヴァルデス，アレクサンダー
ロスコット，スティーブン
シュエ，シャオファ
Original Assignee
ヤンセン ファーマシューティカ エヌ．ベー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン ファーマシューティカ エヌ．ベー． filed Critical ヤンセン ファーマシューティカ エヌ．ベー．
Publication of JP2023524018A publication Critical patent/JP2023524018A/ja
Publication of JP2023524018A5 publication Critical patent/JP2023524018A5/ja
Publication of JPWO2021222404A5 publication Critical patent/JPWO2021222404A5/ja
Application granted granted Critical
Publication of JP7664947B2 publication Critical patent/JP7664947B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Lubricants (AREA)
  • Fats And Perfumes (AREA)
  • Cosmetics (AREA)
JP2022565972A 2020-04-30 2021-04-28 Ｉｌ－１７の調節因子としてのイミダゾリダジン Active JP7664947B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063017682P 2020-04-30 2020-04-30
US63/017,682 2020-04-30
PCT/US2021/029641 WO2021222404A1 (en) 2020-04-30 2021-04-28 Imidazopyridazines as modulators of il-17

Publications (4)

Publication Number Publication Date
JP2023524018A JP2023524018A (ja) 2023-06-08
JP2023524018A5 JP2023524018A5 (https=) 2024-05-09
JPWO2021222404A5 JPWO2021222404A5 (https=) 2024-05-09
JP7664947B2 true JP7664947B2 (ja) 2025-04-18

Family

ID=76197556

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022565972A Active JP7664947B2 (ja) 2020-04-30 2021-04-28 Ｉｌ－１７の調節因子としてのイミダゾリダジン

Country Status (20)

Country Link
US (3) US11691979B2 (https=)
EP (1) EP4143195B1 (https=)
JP (1) JP7664947B2 (https=)
KR (1) KR20230019507A (https=)
CN (1) CN115884810B (https=)
AR (1) AR121959A1 (https=)
AU (1) AU2021264528A1 (https=)
BR (1) BR112022021962A2 (https=)
CA (1) CA3181676A1 (https=)
CO (1) CO2022017072A2 (https=)
EC (1) ECSP22091485A (https=)
ES (1) ES3036330T3 (https=)
IL (1) IL297705A (https=)
JO (1) JOP20220284A1 (https=)
MX (1) MX2022013647A (https=)
PE (1) PE20230469A1 (https=)
TW (1) TWI874645B (https=)
UY (1) UY39188A (https=)
WO (1) WO2021222404A1 (https=)
ZA (1) ZA202212967B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201909190D0 (en) 2019-06-26 2019-08-07 Ucb Biopharma Sprl Therapeutic agents
KR20230019507A (ko) * 2020-04-30 2023-02-08 얀센 파마슈티카 엔.브이. Il-17의 조절제로서의 이미다조피리다진
WO2021220183A1 (en) 2020-04-30 2021-11-04 Janssen Pharmaceutica Nv Imidazopyrimidines as modulators of il-17
CA3200594A1 (en) * 2020-12-14 2022-06-23 UCB Biopharma SRL Imidazopyridazine derivatives as il-17 modulators
WO2023025783A1 (en) 2021-08-23 2023-03-02 Leo Pharma A/S Small molecule modulators of il-17
KR20240082371A (ko) 2021-09-27 2024-06-10 얀센 파마슈티카 엔브이 이미다조피리다진 il-17 억제제 화합물
JP2024536869A (ja) 2021-09-27 2024-10-08 ヤンセン ファーマシューティカ エヌ．ベー． イミダゾピリダジンｉｌ－１７阻害剤化合物
WO2023111181A1 (en) 2021-12-16 2023-06-22 Leo Pharma A/S Small molecule modulators of il-17
CN118580191A (zh) * 2022-01-28 2024-09-03 和记黄埔医药（上海）有限公司 用于制备咪唑并[1,2-b]哒嗪类化合物的中间体
WO2023166172A1 (en) 2022-03-04 2023-09-07 Leo Pharma A/S Small molecule modulators of il-17
EP4525987A1 (en) * 2022-05-19 2025-03-26 Dice Alpha, Inc. Lactam substituted imidazopyridazine il-17a modulators and uses thereof
TW202430165A (zh) 2022-12-02 2024-08-01 丹麥商理奧藥品公司 Il-17之小分子調節劑
CN115806503B (zh) * 2022-12-02 2025-03-07 中国海洋大学 一种选择性组蛋白去乙酰化酶抑制剂及其制备方法和应用
CN121311483A (zh) * 2023-03-28 2026-01-09 詹森药业有限公司 含内酰胺的咪唑并哒嗪il-17抑制剂化合物
KR20250168657A (ko) * 2023-04-11 2025-12-02 다이스 알파, 인크. 치환된 6-이미다조피리다진 il-17a 조정제 및 그의 용도
WO2025202931A1 (en) 2024-03-27 2025-10-02 Janssen Pharmaceutica Nv Imidazopyridazine il-17 inhibitor compounds
WO2025247285A1 (zh) * 2024-05-28 2025-12-04 西藏海思科制药有限公司 一种可抑制il-17a的杂环化合物制备及其用途
WO2026080825A1 (en) * 2024-10-10 2026-04-16 Revolution Medicines, Inc. Synthesis of ras inhibitors

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014039595A1 (en) 2012-09-06 2014-03-13 Bristol-Myers Squibb Company Imidazopyridazine jak3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases
JP2019501125A (ja) 2015-11-18 2019-01-17 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ＩＬ−１２、ＩＬ−２３および／またはＩＦＮα応答のモジュレーターとして有用なイミダゾピリダジン化合物
WO2019138017A1 (en) 2018-01-15 2019-07-18 Ucb Biopharma Sprl Fused imidazole derivatives as il-17 modulators
JP2022516654A (ja) 2019-01-07 2022-03-01 イーライ リリー アンド カンパニー イミダゾ［１，２－ｂ］ピリダジンｉｌ－１７ａ阻害剤

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10208349B2 (en) 2011-01-07 2019-02-19 Ucb Biopharma Sprl Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
US9284283B2 (en) 2012-02-02 2016-03-15 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating IL-17
WO2014066726A2 (en) 2012-10-26 2014-05-01 Ensemble Therapeutics Corporation Compounds for modulating il-17
WO2014181287A1 (en) 2013-05-09 2014-11-13 Piramal Enterprises Limited Heterocyclyl compounds and uses thereof
US10035777B2 (en) 2014-08-05 2018-07-31 Bristol-Myers Squibb Company Heterocyclic kinase inhibitors
GB201709456D0 (en) 2017-06-14 2017-07-26 Ucb Biopharma Sprl Therapeutic agents
WO2019223718A1 (zh) 2018-05-22 2019-11-28 成都先导药物开发股份有限公司 一种免疫调节剂
EP3599245A1 (en) 2018-07-27 2020-01-29 Dompé farmaceutici S.p.A. Il-17a binding polypeptides and medical uses thereof
GB201820166D0 (en) 2018-12-11 2019-01-23 Ucb Biopharma Sprl Therapeutic agents
GB201820165D0 (en) 2018-12-11 2019-01-23 Ucb Biopharma Sprl Therapeutic agents
GB201820316D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for IL-17
BR112021010453A2 (pt) 2018-12-19 2021-08-24 Leo Pharma A/S Composto, e, composição farmacêutica
TWI839461B (zh) 2019-02-06 2024-04-21 美商戴斯阿爾法股份有限公司 Il-17a調節物及其用途
US20220162191A1 (en) 2019-03-08 2022-05-26 Leo Pharma A/S Small molecule modulators of il-17
GB201909190D0 (en) 2019-06-26 2019-08-07 Ucb Biopharma Sprl Therapeutic agents
GB201909191D0 (en) 2019-06-26 2019-08-07 Ucb Biopharma Sprl Therapeutic agents
GB201909194D0 (en) 2019-06-26 2019-08-07 Ucb Biopharma Sprl Therapeutic agents
CN112341441B (zh) 2019-08-09 2022-02-11 成都先导药物开发股份有限公司 一种免疫调节剂
CN112341429B (zh) 2019-08-09 2021-11-23 成都先导药物开发股份有限公司 一种免疫调节剂的中间体化合物
CN112341451B (zh) 2019-08-09 2022-06-17 成都先导药物开发股份有限公司 一种免疫调节剂
WO2021027722A1 (zh) 2019-08-09 2021-02-18 成都先导药物开发股份有限公司 一种免疫调节剂
CN112341442B (zh) 2019-08-09 2021-10-22 成都先导药物开发股份有限公司 一种免疫调节剂
CN112341435B (zh) 2019-08-09 2021-10-22 成都先导药物开发股份有限公司 一种免疫调节剂
WO2021027729A1 (zh) 2019-08-09 2021-02-18 成都先导药物开发股份有限公司 一种免疫调节剂
WO2021027724A1 (zh) 2019-08-09 2021-02-18 成都先导药物开发股份有限公司 一种免疫调节剂
CN112341450B (zh) 2019-08-09 2022-05-17 成都先导药物开发股份有限公司 一种免疫调节剂
WO2021170627A1 (en) 2020-02-25 2021-09-02 UCB Biopharma SRL Difluorocyclohexyl derivatives as il-17 modulators
WO2021170631A1 (en) 2020-02-25 2021-09-02 UCB Biopharma SRL Difluorocyclohexyl derivatives as il-17 modulators
CA3179686A1 (en) 2020-04-07 2021-10-14 UCB Biopharma SRL Difluorocyclohexyl derivatives as il-17 modulators
WO2021204800A1 (en) 2020-04-07 2021-10-14 UCB Biopharma SRL Difluorocyclohexyl derivatives as il-17 modulators
MX2022013649A (es) * 2020-04-30 2023-02-01 Janssen Pharmaceutica Nv Métodos para identificar moduladores de la ruta de il-17.
KR20230019507A (ko) * 2020-04-30 2023-02-08 얀센 파마슈티카 엔.브이. Il-17의 조절제로서의 이미다조피리다진

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014039595A1 (en) 2012-09-06 2014-03-13 Bristol-Myers Squibb Company Imidazopyridazine jak3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases
JP2019501125A (ja) 2015-11-18 2019-01-17 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ＩＬ−１２、ＩＬ−２３および／またはＩＦＮα応答のモジュレーターとして有用なイミダゾピリダジン化合物
WO2019138017A1 (en) 2018-01-15 2019-07-18 Ucb Biopharma Sprl Fused imidazole derivatives as il-17 modulators
JP2022516654A (ja) 2019-01-07 2022-03-01 イーライ リリー アンド カンパニー イミダゾ［１，２－ｂ］ピリダジンｉｌ－１７ａ阻害剤

Also Published As

Publication number Publication date
PE20230469A1 (es) 2023-03-14
US20220402922A1 (en) 2022-12-22
US11702422B2 (en) 2023-07-18
WO2021222404A1 (en) 2021-11-04
BR112022021962A2 (pt) 2023-03-28
JP2023524018A (ja) 2023-06-08
EP4143195B1 (en) 2025-05-21
ZA202212967B (en) 2024-06-26
KR20230019507A (ko) 2023-02-08
US12024524B2 (en) 2024-07-02
ECSP22091485A (es) 2022-12-30
TW202208367A (zh) 2022-03-01
JOP20220284A1 (ar) 2022-10-30
CN115884810A (zh) 2023-03-31
CN115884810B (zh) 2025-01-17
MX2022013647A (es) 2023-02-01
UY39188A (es) 2021-10-29
ES3036330T3 (en) 2025-09-17
US11691979B2 (en) 2023-07-04
IL297705A (en) 2022-12-01
US20230357254A1 (en) 2023-11-09
CA3181676A1 (en) 2021-11-04
AR121959A1 (es) 2022-07-27
EP4143195A1 (en) 2023-03-08
EP4143195C0 (en) 2025-05-21
CO2022017072A2 (es) 2022-12-09
AU2021264528A1 (en) 2023-01-19
US20230081548A1 (en) 2023-03-16
TWI874645B (zh) 2025-03-01

Similar Documents

Publication Publication Date Title
JP7664947B2 (ja) Ｉｌ－１７の調節因子としてのイミダゾリダジン
JP7558334B2 (ja) ＰＩ３Ｋ－γ阻害剤としてのアミノピラジンジオール化合物
CN116531380B (zh) 用于治疗癌症的2-杂芳基-3-氧代-2,3-二氢哒嗪-4-甲酰胺
JP6670756B2 (ja) ブルトン型チロシンキナーゼ（ｂｔｋ）インヒビターとしての多フルオロ置換化合物
JP2024009851A (ja) Ｐｄ－１／ｐｄ－ｌ１阻害剤
JP6964576B2 (ja) 置換４−アザインドール及びｇｌｕｎ２ｂ受容体調節因子としてのそれらの使用
US10287286B2 (en) Compounds
JP7661361B2 (ja) Ｉｌ－１７のモジュレーターとしてのイミダゾピリミジン
KR20240006606A (ko) Nav1.8 억제제로서의 아릴 3-옥소피페라진 카르복스아미드 및 헤테로아릴 3-옥소피페라진 카르복스아미드
CN106795147B (zh) 作为β-分泌酶抑制剂的环丙基稠合噻嗪-2-胺化合物和使用方法
JP2024536862A (ja) Ｉｌ－１７の調節因子としてのベンズイミダゾール
JP6334066B2 (ja) ヤヌスキナーゼ阻害剤としての置換されたＮ−（ピロリジン−３−イル）−７Ｈ−ピロロ［２，３−ｄ］ピリミジン−４−アミン
CN118488953A (zh) 用作单酰基甘油脂肪酶抑制剂的双环杂环化合物
EA049631B1 (ru) Имидазопиридазины в качестве модуляторов il-17
TW202606688A (zh) 用於治療癌症之ｃｄｋ２抑制劑

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240424

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240424

TRDD Decision of grant or rejection written
A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250321

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250325

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250408

R150 Certificate of patent or registration of utility model

Ref document number: 7664947

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150